Cala Health Hopes To Jolt Essential Tremor Market With Wrist-Worn Non-Invasive Stimulation

Cala Health’s FDA-cleared Cala Trio wearable for treating essential tremor is currently being tested in Parkinson’s disease patients and is targeting a $20bn global market opportunity.

Start-up Spotlight

This week, the Burlingame-based bioelectronic medicine company announced it received $77m in new funding, led by Ascension Ventures and new investors Dolby Family Ventures, Peak6 Strategic Capital, a division of PEAK6 Investments, and Innovatus Capital Partners. The company said it will use the new financing to expand patient access, accelerate innovation and explore indications including in Parkinson’s disease as well as psychiatry, cardiology and autoimmune disease.

John Kuelper, head of Healthcare Technology Investing at Ascension Ventures, believes that Cala Health, Inc. is poised to change...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Digital Technologies

More from Medtech Insight